Earla JR - Search Results

1

Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis.

Earla JR, Li J, Hutton GJ, Johnson ML, Aparasu RR. Earla JR, et al. Pharmacotherapy. 2023 Jun;43(6):473-484. doi: 10.1002/phar.2810. Epub 2023 May 22. Pharmacotherapy. 2023. PMID: 37157135

2

How Useful Are Digital Health Terms for Outcomes Research? An ISPOR Special Interest Group Report.

Burrell A, Zrubka Z, Champion A, Zah V, Vinuesa L, Holtorf AP, Di Bidino R, Earla JR, Entwistle J, Boltyenkov AT, Braileanu G, Kolasa K, Roydhouse J, Asche C; ISPOR Digital Health Special Interest Group Key Project. Burrell A, et al. Among authors: earla jr. Value Health. 2022 Sep;25(9):1469-1479. doi: 10.1016/j.jval.2022.04.1730. Value Health. 2022. PMID: 36049797 Free article. Review.

3

Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data.

Earla JR, Paranjpe R, Kachru N, Hutton GJ, Aparasu RR. Earla JR, et al. Res Social Adm Pharm. 2020 Dec;16(12):1670-1676. doi: 10.1016/j.sapharm.2020.02.016. Epub 2020 Mar 11. Res Social Adm Pharm. 2020. PMID: 32171597

4

Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015.

Earla JR, Thornton JD, Hutton GJ, Aparasu RR. Earla JR, et al. J Manag Care Spec Pharm. 2020 Jun;26(6):741-749. doi: 10.18553/jmcp.2020.26.6.741. J Manag Care Spec Pharm. 2020. PMID: 32463779 Free PMC article.

5

Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records.

Earla JR, Hutton GJ, Thornton JD, Aparasu RR. Earla JR, et al. Mult Scler Relat Disord. 2020 Oct;45:102334. doi: 10.1016/j.msard.2020.102334. Epub 2020 Jun 24. Mult Scler Relat Disord. 2020. PMID: 32629400

6

Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.

Aparasu RR, Sura S, Earla JR, Shiozawa A, Ng DB, Schermer CR. Aparasu RR, et al. Among authors: earla jr. Adv Ther. 2020 Aug;37(8):3584-3605. doi: 10.1007/s12325-020-01412-z. Epub 2020 Jul 7. Adv Ther. 2020. PMID: 32638205 Free PMC article.

7

Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis.

Earla JR, Hutton GJ, Thornton JD, Chen H, Johnson ML, Aparasu RR. Earla JR, et al. Patient Prefer Adherence. 2020 Nov 4;14:2187-2199. doi: 10.2147/PPA.S270557. eCollection 2020. Patient Prefer Adherence. 2020. PMID: 33177813 Free PMC article.

8

Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis.

Earla JR, Hutton GJ, Thornton DJ, Chen H, Johnson ML, Aparasu RR. Earla JR, et al. Pharmacotherapy. 2021 May;41(5):440-450. doi: 10.1002/phar.2517. Epub 2021 Mar 18. Pharmacotherapy. 2021. PMID: 33641232

9

Prescribing of disease modifying agents in older adults with multiple sclerosis.

Talwar A, Earla JR, Hutton GJ, Aparasu RR. Talwar A, et al. Among authors: earla jr. Mult Scler Relat Disord. 2022 Jan;57:103308. doi: 10.1016/j.msard.2021.103308. Epub 2021 Oct 5. Mult Scler Relat Disord. 2022. PMID: 35158421

10

FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS.

Li J, Chikermane SG, Earla JR, Hutton GJ, Aparasu RR. Li J, et al. Among authors: earla jr. Mult Scler Relat Disord. 2022 Apr;60:103703. doi: 10.1016/j.msard.2022.103703. Epub 2022 Feb 26. Mult Scler Relat Disord. 2022. PMID: 35278846

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters